Team reports first response of central nervous system tumor to CAR …Medical XpressIn a letter to the New England Journal of Medicine, a Massachusetts General Hospital (MGH) research team reports a remarkable treatment response in a …and more&n… Continue reading
OncLiveDr. Daud Discusses the Current Status of Immunotherapy in MelanomaOncLiveAdil Daud, MD, clinical professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, at University of California, San Francisco, discusses the curren… Continue reading
Gloucestershire LiveMS sufferer gets pioneering stem cell treatmentGloucestershire LiveThe stem cells have been frozen and will be reintroduced to his body after another aggressive course of chemotherapy. It will be fed directly into a main artery in h… Continue reading
Gloucestershire LiveMS sufferer gets pioneering stem cell treatmentGloucestershire LiveThe stem cells have been frozen and will be reintroduced to his body after another aggressive course of chemotherapy. It will be fed directly into a main artery in h… Continue reading
STAT |
Gilead’s Plan? Cash In on CAR–T
Motley Fool The Swiss biopharma Goliath Novartis is the only other drug developer to have a CAR–T that’s pending approval from the FDA. In Kite Pharma’s case, it’s awaiting an FDA decision on axi-cel, a CAR–T that’s under priority review for use in patients with B … Gilead just handed a revolutionary kind of cancer treatment a $12 billon endorsementBusiness Insider Gilead agrees to buy Kite Pharma, leaping into CAR–T cancer therapySTAT The Promising New Cancer Treatment Behind Gilead’s $11 Billion DealFox Business Barron’s –Reuters –Markets Insider –Zacks Investment Research all 244 news articles » |
STAT |
Gilead’s Plan? Cash In on CAR–T
Motley Fool The Swiss biopharma Goliath Novartis is the only other drug developer to have a CAR–T that’s pending approval from the FDA. In Kite Pharma’s case, it’s awaiting an FDA decision on axi-cel, a CAR–T that’s under priority review for use in patients with B … Gilead just handed a revolutionary kind of cancer treatment a $12 billon endorsementBusiness Insider Gilead agrees to buy Kite Pharma, leaping into CAR–T cancer therapySTAT The Promising New Cancer Treatment Behind Gilead’s $11 Billion DealFox Business Barron’s –Reuters –Markets Insider –Zacks Investment Research all 244 news articles » |
|
The Promising New Cancer Treatment Behind Gilead’s $11 Billion …
Fox Business Gilead Sciences Inc.’s planned acquisition of Kite Pharma Inc. underscores the promise of a new type of cancer therapy that is on the brink of becoming … |